Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

• Rosario Pivonello,
• Irina Bancos,
• Richard A. Feelders,
• Atil Y. Kargi,
• Janice M. Kerr,
• Murray B. Gordon,
• Cary N. Mariash,
• Massimo Terzolo,
• Noel Ellison,
• Andreas G. Moraitis

Affiliations

Rosario Pivonello

Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy

Irina Bancos

Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, United States

Richard A. Feelders

Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands

Atil Y. Kargi

Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL, United States

Janice M. Kerr

Department of Endocrinology, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, United States

Murray B. Gordon

Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, United States

Cary N. Mariash

Methodist Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States

Massimo Terzolo

Department of Clinical and Biological Sciences, Internal Medicine 1 − San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy

Noel Ellison

Trialwise, Inc, Houston, TX, United States

Andreas G. Moraitis

0Corcept Therapeutics, Menlo Park, CA, United States